Stem Cell Treatment

Stem Cell Implantation: Millions of MSC stem cells from the umbilical cord are inserted through retrobulbar injection as well as an IV infusion to stimulate dormant optic cells and grow micro blood vessels. These stem cells are at present being investigated for their potential to repair damaged retinal pigment epithelial cells. Retrobulbar injections are usually used worldwide to provide local anesthesia in the retrobulbar area (behind the globe of the eye). During stem cell treatment, this type of injection is utilized to deliver stem cells as close as possible from the retina or the optic nerve in order to better target the site of injury.

In order to speed up the absorption of the stem cell to the retina and optimize the function, we also provide acupuncture, Chinese herbal injections, and hyperbaric oxygen therapy.

On August 14, 2020, Chinese scientists published a research paper about the new solution for late-stage RP. Intravenous infusion of umbilical cord mesenchymal stem cells maintains and partially improves visual function in advanced RP patients.

Inflammatory and immune disorders are thought to play an important role in the pathogenesis of RP. Human umbilical cord mesenchymal stem cells, with multiple biological functions such as anti-inflammation and immunoregulation, have been applied in different systemic diseases.

We conducted a phase I/II clinical trial aiming to evaluate the safety and efficacy of intravenous administration of umbilical cord mesenchymal stem cells in advanced RP patients.

All 32 subjects were intravenously infused with stem cells and were followed up for 12 months. No serious adverse effects occurred in the whole follow-up. Most of the patients (81.3%) maintained or improved their visual acuities for 12 months.

Our results indicated that the intravenous infusion of umbilical cord mesenchymal stem cells was safe for advanced RP patients. Most of the patients improved or maintained their visual functions in a long term.

The life qualities were improved significantly, suggesting that the intravenous infusion of stem cells may be a promising therapeutic approach for advanced RP patients.